Tarsus Pharmaceuticals, Inc. TARS Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s other income, net (note 6)?
- Tarsus Pharmaceuticals, Inc. (TARS) reported other income, net (note 6) of -$87K in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s other income, net (note 6) changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s other income, net (note 6) decreased by 7.4% year-over-year, from -$81K to -$87K.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s other income, net (note 6)?
- Over 3 years (2021 to 2025), Tarsus Pharmaceuticals, Inc.'s other income, net (note 6) has grown at a 40.4% compound annual growth rate (CAGR), from -$73K to -$202K.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.